Samsung Bioepis acquires approval of ‘Brenzys’ in Canada

Published: 2016-09-19 10:07:46

Updated: 2016-09-19 10:07:46

Samsung Bioepis weighed anchor to enter the U.S. market with its first self-developed biosimilar.

On the 12^th, Samsung Bioepis(CEO Han-Seung Ko) announced it acquired sale approval of the Enbrel(etanercept) biosimilar Brenzys(SB4, European name: Benepali) in Canada on the 31^st of the last month.

Enbrel is a biomedicine which recorded approximately KRW 10 trillion sales in the world last yea...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.